menu
    • menu
    [{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"CCAAT\/-binding protein alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"saRNA therapies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Servier"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"RNA-based Medicine","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":1.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":1.25,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"RNA-based Medicines","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MTL-CEBPA","moa":"C\/EBP-alpha protein","graph1":"Oncology","graph2":"Phase II","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Bayer","highestDevelopmentStatusID":"8","companyTruncated":"Mina Therapeutics \/ Bayer"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNAa-based Therapy","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Nippon Shinyaku"}]

    Find Clinical Drug Pipeline Developments & Deals by Mina Therapeutics

    Menu

    Mina Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNAa-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery Platform

                            Sponsor : Nippon Shinyaku

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Collaborates with Nippon Shinyaku On RNAa Therapies

                            Details : MiNA Therapeutics will use its RNAa algorithm and platform to identify RNAa molecules targeting rare CNS genetic diseases under the collaboration.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 04, 2024

                            Lead Product(s) : RNAa-based Therapy

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery Platform

                            Sponsor : Nippon Shinyaku

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTL-CEBPA,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer

                            Details : OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.

                            Brand Name : MTL-CEBPA

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 25, 2022

                            Lead Product(s) : MTL-CEBPA,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Bayer AG

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Medicines

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Announces Equity Investment from Lilly

                            Details : Proceeds from the equity investment will be used to advance and expand MiNA’s internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 06, 2021

                            Lead Product(s) : RNA-based Medicines

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $15.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Medicine

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,250.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly and MiNA Therapeutics Announce saRNA Research Collaboration

                            Details : MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas. Lilly will conduct preclinical and clinical activities of candidates and will retain commerci...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $25.0 million

                            May 11, 2021

                            Lead Product(s) : RNA-based Medicine

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,250.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTL-CEBPA,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination...

                            Details : MTL-CEBPA is the first candidate from MiNA’s pipeline of small activating RNA therapeutics. In pre-clinical studies, MTL-CEBPA was shown to counteract a key cancer immune evasion pathway by inhibiting immune suppression by myeloid cells.

                            Brand Name : MTL-CEBPA

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 09, 2021

                            Lead Product(s) : MTL-CEBPA,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : saRNA therapies

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Servier

                            Deal Size : $262.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

                            Details : As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 21, 2021

                            Lead Product(s) : saRNA therapies

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Servier

                            Deal Size : $262.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTL-CEBPA,Sorafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib i...

                            Details : Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 29, 2020

                            Lead Product(s) : MTL-CEBPA,Sorafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTL-CEBPA,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA

                            Details : The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 03, 2020

                            Lead Product(s) : MTL-CEBPA,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : saRNA

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases

                            Details : The collaboration combines MiNA's expertise in the discovery & development of saRNA therapeutics with AstraZeneca's experience in bringing breakthrough treatments to patients with metabolic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 07, 2020

                            Lead Product(s) : saRNA

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth